ArticleJournal of veterinary pharmacology and therapeutics2014
Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats.
Article in Journal of veterinary pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- 2026 iCatCare consensus guidelines on the diagnosis and management of chronic kidney disease in cats.Journal of feline medicine and surgery · 2026Guideline
- Pharmacokinetics and bioavailability study of two ondansetron oral soluble film formulations in fasting healthy male Chinese volunteers.Drug design, development and therapy · 2015Trial
- The Pharmacokinetics of Intravenous and Subcutaneous Ondansetron in Female Beagle Dogs.Journal of veterinary pharmacology and therapeutics · 2026Article
- Bioavailability of Oral Ondansetron in Dogs: A Crossover Study.Journal of veterinary pharmacology and therapeutics · 2026Article
- Plasma Concentrations of Oral Ondansetron in Hospitalized Dogs Exhibiting Clinical Signs of Nausea.Veterinary sciences · 2024Article
- 2023 AAFP/IAAHPC feline hospice and palliative care guidelines.Journal of feline medicine and surgery · 2023Review
- Pharmacokinetics and anti-nausea effects of intravenous ondansetron in hospitalized dogs exhibiting clinical signs of nausea.Journal of veterinary pharmacology and therapeutics · 2022Article
- 2022 ISFM Consensus Guidelines on Management of the Inappetent Hospitalised Cat.Journal of feline medicine and surgery · 2022Article
- Drug-Dosing Adjustment in Dogs and Cats with Chronic Kidney Disease.Animals : an open access journal from MDPI · 2022Review
- The use of ondansetron for the treatment of nausea in dogs with vestibular syndrome.BMC veterinary research · 2021Article
- Feline comorbidities: What do we really know about feline triaditis?Journal of feline medicine and surgery · 2020Review
- Preparation of an oil suspension containing ondansetron hydrochloride as a sustained release parenteral formulation.Drug delivery and translational research · 2020Article
- Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats.Journal of feline medicine and surgery · 2018Article
- Assessment of absorption of transdermal ondansetron in normal research cats.Journal of feline medicine and surgery · 2017Article
- Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease, and cats with liver disease.Journal of veterinary pharmacology and therapeutics · 2016Article
- ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease.Journal of feline medicine and surgery · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Ondansetron is a 5-HT3 receptor antagonist that is an effective anti-emetic in cats. The purpose of this study was to evaluate the pharmacokinetics of ondansetron in healthy cats. Six cats with normal complete blood count, serum biochemistry, and urinalysis received 2 mg oral (mean 0.43 mg/kg), subcutaneous (mean 0.4 mg/kg), and intravenous (mean 0.4 mg/kg) ondansetron in a cross-over manner with a 5-day wash out. Serum was collected prior to, and at 0.25, 0.5, 1, 2, 4, 8, 12, 18, and 24 h after administration of ondansetron. Ondansetron concentrations were measured using liquid chromatography coupled to tandem mass spectrometry. Noncompartmental pharmacokinetic modeling and dose interval modeling were performed. Repeated measures anova was used to compare parameters between administration routes. Bioavailability of ondansetron was 32% (oral) and 75% (subcutaneous). Calculated elimination half-life of ondansetron was 1.84 ± 0.58 h (intravenous), 1.18 ± 0.27 h (oral) and 3.17 ± 0.53 h (subcutaneous). The calculated elimination half-life of subcutaneous ondansetron was significantly longer (P < 0.05) than oral or intravenous administration. Subcutaneous administration of ondansetron to healthy cats is more bioavailable and results in a more prolonged exposure than oral administration. This information will aid management of emesis in feline patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.